Opioids for the Treatment of Pain in the Rehabilitation Patient


Drug

Strength relative to morphine

Usual starting oral dose (mg)

Dosing interval (h)

Onset (min)

Morphine

1

10–30

IR: 3–4

30–45

ER: 12

Hydromorphone

5

2–4

4–6

30

Oxycodone

1.5–2

5–15

4–6

30–60

Methadone

7.5

2.5–10

8–12

60–90

Oxymorphone

7

5

12

30–60




Table 30.2
Bioavailability, half-life, and duration of commonly used opioid analgesics







































Drug

Bioavailability-oral (%)

Half-life (h)

Duration (h)

Morphine

30–40

2–4

3–4

Hydromorphone

25

2–3

2–3

Oxycodone

60–80

3–4

4–6

Methadone

80

22

6–12

Oxymorphone

10

6–8

3–4


A334608_1_En_30_Fig1_HTML.gif


Fig. 30.1
Strength of opioids


Oxycodone is predominantly a pro-drug and undergoes hepatic metabolism via cytochrome P450 2D6 enzyme, where it is converted to oxymorphone, an active metabolite with mu opioid agonist properties, and noroxycodone, an inactive metabolite. The kidneys excrete oxycodone; therefore , the dose should be adjusted in renal dysfunction.



Oxymorphone


Oxymorphone is a semi-synthetic opioid that has been available as an oral formulation since 2006. Oxymorphone is primarily a mu opioid receptor agonist that has more affinity for the mu opioid receptor than morphine and is ten times as potent as morphine when given IV. Oxymorphone has greater affinity for the delta receptor, with agonism decreasing tolerance, and less affinity for the kappa opioid receptor unlike oxycodone. Like fentanyl, oxymorphone has less histamine release from mast cells than morphine and is more lipid soluble than morphine and oxycodone. The increase in lipophilicity leads to maximum plasma concentrations in 30 min as compared to morphine IR in 1.2 h.

Oxymorphone’s bioavailability is only 10%, due to extensive first-pass hepatic metabolism; however, greater lipid solubility facilitates its ability to cross the blood brain barrier (BBB) and may account for its rapid onset of analgesia. For immediate release (IR) formulations, onset of analgesia is 30–60 min, with predictable dosing. For extended or sustained release (ER/SR) formulations, steady state occurs in 3 days with every 12 h dosing.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Aug 26, 2017 | Posted by in Uncategorized | Comments Off on Opioids for the Treatment of Pain in the Rehabilitation Patient

Full access? Get Clinical Tree

Get Clinical Tree app for offline access